Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Xie, S. H. Wei, M. He (Guangzhou, Beijing, Shanghai, China). Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib. Eur Respir J 2014; 44: Suppl. 58, 507

Member's Comments

No comment yet.

Related content which might interest you: The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC) Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 The prognostic value of KRAS mutation according to the gene's Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Functional impairment of NK cells in non-small-cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014